JP5059996B2 - 新規インターロイキン−１および腫瘍壊死因子−αモジュレーター、前記モジュレーターの合成、ならびに前記モジュレーターの使用方法 - Google Patents

新規インターロイキン−１および腫瘍壊死因子−αモジュレーター、前記モジュレーターの合成、ならびに前記モジュレーターの使用方法 Download PDF

Info

Publication number
JP5059996B2
JP5059996B2 JP2000621320A JP2000621320A JP5059996B2 JP 5059996 B2 JP5059996 B2 JP 5059996B2 JP 2000621320 A JP2000621320 A JP 2000621320A JP 2000621320 A JP2000621320 A JP 2000621320A JP 5059996 B2 JP5059996 B2 JP 5059996B2
Authority
JP
Japan
Prior art keywords
alkenyl
alkyl
compound
hydrogen
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000621320A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003500464A (ja
JP2003500464A5 (https=
Inventor
パラディノ，マイケル
エー． セオドラキス，エマニュエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of JP2003500464A publication Critical patent/JP2003500464A/ja
Publication of JP2003500464A5 publication Critical patent/JP2003500464A5/ja
Application granted granted Critical
Publication of JP5059996B2 publication Critical patent/JP5059996B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/32—Unsaturated compounds containing hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/28—Unsaturated compounds polycyclic
    • C07C61/29—Unsaturated compounds polycyclic having a carboxyl group bound to a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/35—Unsaturated compounds having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/753—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of polycyclic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
JP2000621320A 1999-05-14 2000-05-12 新規インターロイキン−１および腫瘍壊死因子−αモジュレーター、前記モジュレーターの合成、ならびに前記モジュレーターの使用方法 Expired - Lifetime JP5059996B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13429599P 1999-05-14 1999-05-14
US60/134,295 1999-05-14
US18685300P 2000-03-03 2000-03-03
US60/186,853 2000-03-03
PCT/US2000/013202 WO2000073253A1 (en) 1999-05-14 2000-05-12 NOVEL INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-α MODULATORS, SYNTHESES OF SAID MODULATORS AND METHODS OF USING SAID MODULATORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012137825A Division JP2012211162A (ja) 1999-05-14 2012-06-19 新規インターロイキン−１および腫瘍壊死因子−αモジュレーター、前記モジュレーターの合成、ならびに前記モジュレーターの使用方法

Publications (3)

Publication Number Publication Date
JP2003500464A JP2003500464A (ja) 2003-01-07
JP2003500464A5 JP2003500464A5 (https=) 2007-07-05
JP5059996B2 true JP5059996B2 (ja) 2012-10-31

Family

ID=26832188

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000621320A Expired - Lifetime JP5059996B2 (ja) 1999-05-14 2000-05-12 新規インターロイキン−１および腫瘍壊死因子−αモジュレーター、前記モジュレーターの合成、ならびに前記モジュレーターの使用方法
JP2012137825A Withdrawn JP2012211162A (ja) 1999-05-14 2012-06-19 新規インターロイキン−１および腫瘍壊死因子−αモジュレーター、前記モジュレーターの合成、ならびに前記モジュレーターの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012137825A Withdrawn JP2012211162A (ja) 1999-05-14 2012-06-19 新規インターロイキン−１および腫瘍壊死因子−αモジュレーター、前記モジュレーターの合成、ならびに前記モジュレーターの使用方法

Country Status (17)

Country Link
US (3) US6365768B1 (https=)
EP (2) EP1178952B1 (https=)
JP (2) JP5059996B2 (https=)
KR (3) KR100856353B1 (https=)
CN (1) CN1361760A (https=)
AT (2) ATE370928T1 (https=)
AU (2) AU783372B2 (https=)
BR (1) BR0011522A (https=)
CA (1) CA2372962C (https=)
DE (2) DE60043400D1 (https=)
DK (1) DK1178952T5 (https=)
ES (2) ES2337264T3 (https=)
IL (3) IL146221A0 (https=)
MX (1) MXPA01011613A (https=)
NZ (3) NZ515675A (https=)
PT (2) PT1178952E (https=)
WO (1) WO2000073253A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100566422B1 (ko) * 1998-01-26 2006-04-07 재단법인서울대학교산학협력재단 디테르펜 유도체 및 이를 포함하는 소염진통제
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US7119223B2 (en) 1999-05-14 2006-10-10 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factor-α modulators, synthesis of said modulators and their enantiomers and methods of using said modulators
DE60043400D1 (de) 1999-05-14 2010-01-07 Nereus Pharmaceuticals Inc Interleukin-1 und Tumornekrosefaktor-alpha Modulatoren,Synthese dieser Modulatoren und Methoden zur Anwendung dieser Modulatoren
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
AU2002255963A1 (en) * 2001-03-28 2002-10-15 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factor-alpha modulators and their enantiomers, their synthesis and use
US20030087334A1 (en) * 2001-04-02 2003-05-08 Libraria, Inc. Method of flexibly generating diverse reaction chemistries
US7176237B2 (en) 2002-01-15 2007-02-13 The Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
AU2003206179A1 (en) * 2002-01-25 2003-09-02 Korea Research Institute Of Bioscience And Biotechnology An extract of acanthopanax koreanum for the treatment or prevention of hepatitis or the liver protective drug
US7517542B2 (en) * 2004-03-03 2009-04-14 Korea Research Institute Of Bioscience Abietane diterpenoid compound, and composition comprising extract of torreya nucifera, or abietane diterpenoid compounds or terpenoid compounds isolated from them for prevention and treatment of cardiovascular disease
EP2311795A3 (en) 2005-07-21 2011-12-28 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators
EP2094651A1 (en) 2006-11-17 2009-09-02 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
US8299046B2 (en) 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
EP1925301A1 (en) * 2006-11-24 2008-05-28 DSMIP Assets B.V. Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders
US7875853B2 (en) * 2007-07-23 2011-01-25 Honeywell International Inc. Low-cost PIR scanning mechanism
BRPI0907423A2 (pt) 2008-01-11 2020-10-27 Reata Pharmaceuticals, Inc. composto triterpenoide sintético para uso em um método de melhoria da função renal em um indivíduo, e uso do referido composto
JP5529851B2 (ja) 2008-04-18 2014-06-25 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーター：ｃ−１７においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体
WO2009146218A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
KR101713140B1 (ko) 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
MX2010011439A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Moduladores de inflamacion antioxidantes: derivados del acido oleanolico homologacion c-17.
EP2309860B1 (en) 2008-07-22 2014-01-08 Trustees of Dartmouth College Monocyclic cyanoenones and methods of use thereof
US20110293653A1 (en) * 2010-03-11 2011-12-01 University Of Massachusetts Antagonists of mir-155 for the treatment of inflammatory liver disease
DK2558105T3 (da) 2010-04-12 2020-01-27 Reata Pharmaceuticals Inc Bardoxolonmethyl til behandling af fedme
JP5845274B2 (ja) * 2010-10-27 2016-01-20 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 生物学的特性を賦与されたジテルペノイド誘導体
NZ703649A (en) 2010-12-06 2016-08-26 Penn State Res Found Compositions and methods relating to proliferative diseases
CN103596929B (zh) 2010-12-17 2016-10-19 里亚塔医药公司 作为抗氧化发炎调节剂的吡唑及嘧啶三环烯酮
MX348862B (es) 2011-03-11 2017-07-03 Reata Pharmaceuticals Inc Derivados c4-monometil triterpenoides y sus metodos de uso.
TWI623548B (zh) 2012-04-27 2018-05-11 瑞塔醫藥有限責任公司 齊墩果酸（ｂａｒｄｏｘｏｌｏｎｅ ｍｅｔｈｙｌ）之２，２-二氟基丙醯胺衍生物、多晶型及其使用方法
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
JP6243428B2 (ja) 2012-09-10 2017-12-06 リアタ ファーマシューティカルズ インコーポレイテッド オレアノール酸のｃ１７−アルカンジイルおよびアルケンジイル誘導体ならびにその使用方法
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
JP7074674B2 (ja) 2015-09-23 2022-05-24 リアタ ファーマシューティカルズ インコーポレイテッド Ｉｌ－１７の阻害及び他の使用のためのｃ４修飾オレアノール酸誘導体
CN110198718B (zh) 2016-11-08 2023-01-10 里亚塔医药控股有限责任公司 使用甲基巴多索隆或其类似物治疗阿尔波特综合征的方法
CN106928095A (zh) * 2017-03-14 2017-07-07 华东师范大学 氰基烯酮类三环二萜类似物及其制备方法和应用
US10463631B2 (en) * 2017-06-12 2019-11-05 University Of South Carolina Pimarane diterpenoids for use in wound healing and angiogenesis
US12060340B2 (en) 2018-06-20 2024-08-13 Reata Pharmaceuticals, Inc Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
EP3999522B1 (en) 2019-07-19 2025-09-03 Reata Pharmaceuticals, Inc. C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5212708B2 (https=) 1974-05-14 1977-04-08
JPS522910B2 (https=) 1974-05-17 1977-01-25
GB1452053A (en) 1974-08-28 1976-10-06 Nippon Shinyaku Co Ltd Abietamide derivatives and a method for the preparation thereof
US4874891A (en) 1986-05-01 1989-10-17 Washington University Open "D" ring hormone analogs
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5192817A (en) 1990-03-06 1993-03-09 Otsuka Pharmaceutical Co., Ltd. Phenanthrene derivatives
US5276182A (en) 1990-07-09 1994-01-04 The Dow Chemical Company Process for preparing polyurea oligomers
DE4039602A1 (de) 1990-12-12 1992-06-17 Bauer Kurt Heinz Prof Dr Pharmazeutische formulierungen
KR100221695B1 (ko) 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5653962A (en) 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
AU5612694A (en) 1992-11-27 1994-06-22 Napro Biotherapeutics, Inc. Injectable composition
US5654286A (en) 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
EP1475091A1 (en) 1993-10-01 2004-11-10 Roche Palo Alto LLC Mycophenolate mofetil - high dose oral suspensions
KR0145941B1 (ko) * 1994-06-13 1998-08-17 김은영 인터루킨-1과 종양 괴사 인자-알파의 생산 억제에 유용한 아칸토산을 포함하는 약학적 조성물
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
KR100566422B1 (ko) * 1998-01-26 2006-04-07 재단법인서울대학교산학협력재단 디테르펜 유도체 및 이를 포함하는 소염진통제
US6051590A (en) 1999-05-13 2000-04-18 Merck & Co., Inc. Immunosuppressant tricyclic compounds
DE60043400D1 (de) * 1999-05-14 2010-01-07 Nereus Pharmaceuticals Inc Interleukin-1 und Tumornekrosefaktor-alpha Modulatoren,Synthese dieser Modulatoren und Methoden zur Anwendung dieser Modulatoren
AU2002255963A1 (en) 2001-03-28 2002-10-15 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factor-alpha modulators and their enantiomers, their synthesis and use

Also Published As

Publication number Publication date
ES2337264T3 (es) 2010-04-22
JP2003500464A (ja) 2003-01-07
ES2295031T3 (es) 2008-04-16
DK1178952T5 (da) 2008-03-17
EP1178952B1 (en) 2007-08-22
EP1591437A2 (en) 2005-11-02
US20030040640A1 (en) 2003-02-27
CN1361760A (zh) 2002-07-31
US6365768B1 (en) 2002-04-02
BR0011522A (pt) 2002-06-04
ATE370928T1 (de) 2007-09-15
JP2012211162A (ja) 2012-11-01
KR20060135080A (ko) 2006-12-28
NZ529505A (en) 2005-09-30
KR100856353B1 (ko) 2008-09-04
IL146221A (en) 2007-07-04
CA2372962C (en) 2008-04-08
DE60043400D1 (de) 2010-01-07
AU5013300A (en) 2000-12-18
NZ540001A (en) 2007-06-29
US6881857B2 (en) 2005-04-19
EP1591437B1 (en) 2009-11-25
DE60036101T2 (de) 2008-05-15
ATE449754T1 (de) 2009-12-15
DE60036101D1 (de) 2007-10-04
IL146221A0 (en) 2002-07-25
DK1178952T3 (da) 2008-01-28
AU783372B2 (en) 2005-10-20
IL182272A (en) 2010-05-31
AU2006200240B2 (en) 2009-05-28
HK1084657A1 (en) 2006-08-04
KR100840925B1 (ko) 2008-06-24
AU2006200240A1 (en) 2006-02-16
IL182272A0 (en) 2007-07-24
WO2000073253A1 (en) 2000-12-07
EP1591437A3 (en) 2006-03-08
PT1178952E (pt) 2007-12-04
KR20060110013A (ko) 2006-10-23
US20050209325A1 (en) 2005-09-22
PT1591437E (pt) 2010-03-04
KR20020028878A (ko) 2002-04-17
US7342125B2 (en) 2008-03-11
NZ515675A (en) 2004-06-25
CA2372962A1 (en) 2000-12-07
MXPA01011613A (es) 2003-10-14
EP1178952A1 (en) 2002-02-13

Similar Documents

Publication Publication Date Title
JP5059996B2 (ja) 新規インターロイキン−１および腫瘍壊死因子−αモジュレーター、前記モジュレーターの合成、ならびに前記モジュレーターの使用方法
AU2006276274B2 (en) Interleukin-1 and tumor necrosis factor-a modulators; syntheses of such modulators and methods of using such modulators
HK1084657B (en) Interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators
US20080188475A1 (en) Novel Interleukin-1 and Tumor Necrosis Factor-Alpha Modulators, Syntheses of Said Modulators and Their Enantiomers and Methods of Using Said Modulators
WO2002079137A1 (en) Interleukin-1 and tumor necrosis factor-alpha modulators and their enantiomers, their synthesis and use
AU2012202475A1 (en) Interleukin-1 and tumor necrosis factor-a modulators; syntheses of such modulators and methods of using such modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110301

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120619

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120710

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120803

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150810

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5059996

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term